Since 2003, Dr Johnson has been working in the life science team at Index Ventures (now in spin-off Medixci Ventures), with a focus on drug development companies including Acutus Inc., B3NGF, Levicept Ltd and PanGenetics (acquired by Abbott 2009).
Prior to this, Kevin was CEO of Netherlands-based PanGenetics, an antibody development company. Previously he held various research roles at Cambridge Antibody Technology (CAT) leading to appointment to the board as Research Director and Chief Technology Officer in 1997, where he was responsible for CAT’s platform technologies. Some of the discovered human antibodies are currently in clinical development and two of these, Humira (Abbott Pharmaceutical) and Benlysta (HGS, GSK), are now on the market.
In 1997, he was part of the management team when CAT was listed at the London Stock Exchange. Kevin graduated in Molecular Biology from Edinburgh University and holds a PhD in Pathology from Cambridge University.